Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
Hypothesis:

 Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a
 period of 18 months has anti-inflammatory and neuroprotective properties in patients with
 relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical
 examination (EDSS and MSFC).
This multicentric, national study investigates the efficacy and safety of EGCG in patients
 with relapsing-remitting multiple sclerosis.
Inclusion Criteria:

 -  male and female subjects age 18 to 60

 -  relapsing-remitting course of MS

 -  stable treatment with glatiramer acetate at least 6 months prior to inclusion

 Exclusion Criteria:

 -  primary or secondary progressive forms of MS

 -  clinically relevant heart, lung, liver, kidney diseases

 -  regular hepatotoxic co-medication

 -  drug addiction

 -  alcohol abuse